Status:
COMPLETED
Low-contrast Dose Liver CT Using Lean Body Weight Low Monoenergetic Images and Deep Learning-based Reconstruction
Lead Sponsor:
Seoul National University Hospital
Collaborating Sponsors:
Siemens Corporation, Corporate Technology
Conditions:
Carcinoma, Hepatocellular
Body Weight
Eligibility:
All Genders
20+ years
Phase:
NA
Brief Summary
This study aims to assess whether the acceptable image quality is achievable using low monoenergetic imaging of dual-energy CT with deep learning-based denoising, and low contrast media dose calculate...
Detailed Description
The use of iodinated contrast media in CT is associated with an immediate hypersensitivity reaction in a dose-dependent manner. Therefore, it is important to reduce the contrast dose for CT exams in p...
Eligibility Criteria
Inclusion
- High risk group for developing HCC
- Scheduled contrast-enhanced CT for HCC diagnosis or surveillance
Exclusion
- not a high risk group for developing HCC
- body mass index is equal to or larger than 30 kg/m\^2
- suspected HCC \> 5cm in diameter
- received locoregional treatment or surgery for HCC within 3 months
- congestive hepatopathy
- no venous access on forearm
- anticipated beam hardening artifact due to prosthesis
- relative/absolute contraindication of contrast-enhanced CT
Key Trial Info
Start Date :
June 27 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 10 2022
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT04027556
Start Date
June 27 2019
End Date
February 10 2022
Last Update
May 4 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul National University Hospital
Seoul, South Korea